Justin Morgan, MD
Payments from drug & device makers
Across 457 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- SK Life Science, Inc.$1K
- Novartis$1K
- Pfizer$821
- UCB, Inc.$386
- Biogen$334
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,42298%
- Education$1822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,339 |
| SK Life Science, Inc. | 57 | $1,049 |
| Novartis | 81 | $1,045 |
| Pfizer | 71 | $821 |
| UCB, Inc. | 11 | $386 |
| Biogen | 22 | $334 |
| Teva Pharmaceuticals USA, Inc. | 16 | $311 |
| Biohaven Pharmaceutical Holding Company Ltd. | 26 | $272 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $268 |
| Neurocrine Biosciences, Inc. | 10 | $252 |
| Amgen | 9 | $210 |
| Acadia Pharmaceuticals Inc | 9 | $184 |
| Biohaven Pharmaceuticals, Inc. | 16 | $151 |
| Grifols USA, LLC | 5 | $134 |
| Amneal Pharmaceuticals LLC | 6 | $102 |
| Averitas Pharma Inc. | 4 | $101 |
| Lundbeck LLC | 4 | $85 |
| Abbott | 3 | $75 |
| EMD Serono, Inc. | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $48 |
| Sanofi | 2 | $47 |
| Painteq LLC | 1 | $47 |
| Avion Pharmaceuticals | 2 | $41 |
| Medtronic | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Relievant Medsystems, Inc. | 1 | $23 |
| Nevro Corp. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| SPR Therapeutics, Inc | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Octapharma USA, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
How this compares
$7,605 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 17 | $393,962 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $313,496 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 47 | $311,032 |
| Kesimpta PenOfatumumab | 16 | $162,306 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $29,890 |
| XcopriCenobamate | 15 | $25,110 |
| RytaryCarbidopa/Levodopa | 15 | $16,568 |
| Nurtec OdtRimegepant Sulfate | 13 | $12,433 |
| Lacosamide | 40 | $3,142 |
| Gabapentin | 100 | $2,482 |
| Oxcarbazepine | 19 | $1,625 |
| Memantine Hcl | 53 | $1,567 |
| AmantadineAmantadine Hcl | 41 | $1,485 |
| Levetiracetam | 36 | $1,236 |
| RivastigmineRivastigmine Tartrate | 13 | $839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $134 | $311,03247 claims |
| SK Life Science, Inc.Xcopri | $1,049 | $25,11015 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $102 | $17,38626 claims |
| PfizerNurtec Odt | $821 | $12,43313 claims |
| Upsher-smith Laboratories LLCTopiramate | $19 | $32015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.
Other neurology in Katy
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
- Benjamin GreenbergDallas$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.